Lemborexant, also known as E-2006, is a dual antagonist of the orexin OX1 and OX2 receptors which is under development by Eisai for the treatment of insomnia. As of December 2014, it is in phase II clinical trials.
Chemical Name: (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide
台州市科瑞生物技术有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
crene